BeStock  
Stocks › Drug Manufacturers - General › AMGN

Amgen AMGN

US equityMarket cap rank #68Drug Manufacturers - GeneralCAR-T Therapy
$460.42 +$0.14 (+0.03%)
Market closed · Nov 6, 9:50 pm ET · Last extended-hours $461.50 +0.23%
Open$448.17
Prev close$460.28
Day range$447.04 – $462.91
Volume2.58M
Market cap$249.05B
P/E (TTM)26.7
Dividend yield2.16%

Earnings

Average move on report day±4.7%last 16 reports
Closed higher8 of 1650% of the time
Best reaction+11.8%
Worst reaction-6.4%

Stock move on the day after each report

-2.8%2023/Q3-6.4%2023/Q4+11.8%2024/Q1-5.0%2024/Q2+1.5%2024/Q3+6.5%2024/Q4-0.9%2025/Q1-5.1%2025/Q2+7.8%2025/Q3+8.2%2025/Q4-4.7%2026/Q1+4.6%2026/Q2
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q24 Aug 2026After Market±4.6%+4.57%Bigger than priced
2026/Q130 Apr 2026After Market±5.3%-4.75%Within range
2025/Q43 Feb 2026After Market±4.2%+8.15%Bigger than priced
2025/Q34 Nov 2025After Market±3.9%+7.81%Bigger than priced
2025/Q25 Aug 2025After Market±4.6%-5.14%Bigger than priced
2025/Q11 May 2025After Market±5.5%-0.90%Within range
2024/Q44 Feb 2025After Market±4.3%+6.50%Bigger than priced
2024/Q330 Oct 2024After Market±5.1%+1.46%Within range
2024/Q26 Aug 2024After Market±5.1%-5.00%Within range
2024/Q12 May 2024After Market±5.6%+11.82%Bigger than priced
2023/Q46 Feb 2024After Market±4.5%-6.39%Bigger than priced
2023/Q331 Oct 2023Pre Market±3.8%-2.85%Within range
2023/Q23 Aug 2023After Market±3.8%+5.45%Bigger than priced
2023/Q127 Apr 2023After Market±3.7%-0.25%Within range
2022/Q431 Jan 2023After Market±3.7%-2.37%Within range
2022/Q33 Nov 2022After Market±4.6%+1.19%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q2

By business line

  • Other$3.28B 32.6%
  • Other products$1.70B 16.9%
  • Repatha$953.00M 9.5%
  • Prolia$759.00M 7.5%
  • EVENITY$714.00M 7.1%
  • Enbrel$580.00M 5.8%
  • TEPEZZA$576.00M 5.7%
  • Other revenues$517.00M 5.1%
  • Otezla$491.00M 4.9%
  • TEZSPIRE$486.00M 4.8%

Fundamentals

Full statements →

Latest reported quarter: Q2, ended Jun 2026

Revenue$10.05B+9.5% YoY
Operating profit$3.51B+32.3% YoY
Net profit$2.38B+65.9% YoY
Diluted EPS$4.37+64.9% YoY
Free cash flow$3.49B+82.6% YoY
Operating cash flow$4.00B

Revenue, last 8 quarters

$8.5BSep '24$9.1BDec '24$8.1BMar '25$9.2BJun '25$9.6BSep '25$9.9BDec '25$8.6BMar '26$10.1BJun '26

Net profit, last 8 quarters

$2.8BSep '24$627.0MDec '24$1.7BMar '25$1.4BJun '25$3.2BSep '25$1.3BDec '25$1.8BMar '26$2.4BJun '26

Profitability & balance sheet

Gross margin69.5%
Operating margin30.0%
Net margin23.0%
Return on equity91.5%
Return on assets9.5%
Return on invested capital16.6%
Current ratio1.37
Liabilities / assets87.8%
Cash & investments$13.99B
Total debt$57.30B
Net cash (debt)-$43.32B
Free cash flow / sales26.7%

Discussion

No comments yet — be the first to weigh in on AMGN.

Sign in to join the discussion.

Scroll to Top